Non-surgical ablation for breast cancer: an emerging therapeutic option
- PMID: 38423057
- DOI: 10.1016/S1470-2045(23)00615-0
Non-surgical ablation for breast cancer: an emerging therapeutic option
Abstract
Non-surgical ablation is emerging as an alternative local therapy option for patients with early-stage breast cancer and encompasses two main types of percutaneous therapeutic procedures: radiofrequency ablation and cryoablation. Both techniques involve obliteration of a spherical lesion and feasibility studies have shown that complete tumour ablation is achievable with good or excellent cosmetic results. Although few clinical studies have directly compared non-surgical ablation with conventional surgical resection, observational studies indicate that clinical outcomes are favourable with acceptable rates of local control and no detriment to long-term survival. There remain outstanding issues with these percutaneous ablative techniques that require resolution before they could be incorporated into routine clinical practice. Hence, a consensus meeting was convened to discuss the challenges of non-surgical ablation and clarify indications for its use alongside clinical management pathways. In this Policy Review we will address some of the broader biological aspects of non-surgical ablation, including immune-modulatory effects and potential novel applications for the future.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests MTo has received institutional grants from Kansai Med Net, AFI technology, Eisai, Astellas, Nippon Kayaku, Taiho, Sanwa Syurui, Shimadzu, Chugai, Pfizer, Yakult, Zene, AstraZeneca, and the Japan Breast Cancer Research Group Association (JBCRG); advisory fees from Bertis, Eli Lilly, and Daiichi Sankyo; and personal fees from AstraZeneca, MSD, Eisai, Devicore Medical Japan, Kyowa-Kirin, Daiichi Sankyo, Eli Lilly, Nippon Kayaku, Taiho, Exact Science, Shimadzu, Chugai, Pfizer, Yakult, and Sysmex. MTo is a member of the board of directors of JBCRG and the Kyoto Breast Cancer Research Network (KBCRN); a chairman of JBCRG; and an associate editor of Breast Cancer Research and Treatment, Scientific Reports, and Cancer Science. MTa has received institutional grants from Daiichi Sankyo, AstraZeneca, Yakult, Medbis, Japan Breast Cancer Research Group, Kyoto Breast Cancer Research Network, Austrian Breast and Colorectal Cancer Study Group, Eisai, and IQVIA Japan; and personal fees from Daiichi Sankyo, AstraZeneca, Chugai, Eli Lilly, Pfizer, Taiho, Eisai, MSD, Novartis, Kyowa-Kirin, and Devicore Medical Japan. MTa is a member of the board of directors of JBCRG and KBCRN. All other authors declare no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical